Submitted by Anonymous (not verified) on 5 April 2024 - 14:30
Opinion/decision on a Paediatric investigation plan (PIP): Besponsa, Inotuzumab ozogamicin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Haematology-Hemostaseology;Oncology, PIP number: P/0079/2023
Source: